Clinical Trials Sponsored by Orakine Ltd, Dublin, Ireland

Total 52 results

Assistance Publique - Hôpitaux de Paris
Orakine Ltd, Dublin, Ireland

Terminated

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer (GP-INFA)

Influenza Infection

France
Horizon Pharma Ireland, Ltd., Dublin Ireland

Recruiting

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Sjögren's Syndrome (SS)

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Enrolling by invitation

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Korea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis (SUNRAY)

Rheumatoid Arthritis
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE)

Hepatic Encephalopathy | Cirrhosis

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

Peptic Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Drug Toxicity

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Terminated

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

Ulcer
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Asthma

France
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA)

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis (CAPRA-2)

Rheumatoid Arthritis

United States, Germany, Hungary, Canada, Poland, United Kingdom
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) (HZ-CA-304)

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Horizon Therapeutics Ireland DAC

Recruiting

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (N-MOmentum LT)

Neuromyelitis Optica Spectrum Disorder

Korea, Republic of, Hong Kong, Hungary, Thailand
Horizon Therapeutics Ireland DAC

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

United Kingdom, Brazil, Serbia, United States, Canada, France, Poland, Spain, Sweden, Argentina, Netherlands
Horizon Therapeutics Ireland DAC

Recruiting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Idiopathic Inflammatory Myositis

Mexico, United States, Spain, Australia, Italy, United Kingdom, Czechia, Brazil, Germany
Horizon Therapeutics Ireland DAC

Recruiting

Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus (RECAST DLE)

Discoid Lupus Erythematosus

United States, Germany, Canada, France, Greece, Denmark, Brazil, Bulgaria, Czechia, Argentina, Poland
Horizon Therapeutics Ireland DAC

Recruiting

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | Sclerosis, Systemic

Netherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Completed

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Uncontrolled Gout | Kidney Transplant

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR OL)

Gout

United States
Indiana University
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Use of ACTIMMUNE in Patients With ADO2

Autosomal Dominant Osteopetrosis Type 2

United States
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Sjogren's Syndrome
Horizon Therapeutics Ireland DAC

Recruiting

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Gout

United States
Horizon Therapeutics Ireland DAC

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

Israel, Chile, United States, Argentina, Canada, Japan, Korea, Republic of
Horizon Therapeutics Ireland DAC

Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy Related | Neuromyelitis Optica Spectrum Disorder

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
University of Pittsburgh
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Hepatic Encephalopathy | Urea Cycle Disorders

Ukraine
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

Healthy

Ukraine
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study (STEADFAST)

Friedreich's Ataxia

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia (STEADFAST)

Friedreich's Ataxia

United States
Attune Health Research, Inc.
Horizon Pharma Ireland, Ltd., Dublin Ireland

Active, not recruiting

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Gout

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance

Completed

Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia (STEADFAST)

Friedreich's Ataxia

United States
Fox Chase Cancer Center
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Advanced Solid Tumors

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland
Pediatric Rheumatology Collaborative Study Group

Completed

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States
PulseAI Ltd
Beacon Hospital Research Institute, Dublin, Ireland

Recruiting

Automated Diagnostic Performance of Smartwatch ECG for Arrhythmia Detection Using the PulseAI Neural Network.

Arrhythmias, Cardiac

Ireland
H. Lee Moffitt Cancer Center and Research Institute
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Breast Cancer Female

United States
University of Ulster
DSM Ltd; Public Health Agency (Northern Ireland)

Recruiting

Optimal Nutrition for Prevention of Hypertension in Pregnancy (OptiPREG)

Pregnancy | Blood Pressure

Ireland, United Kingdom

Clinical Trials Sponsored by Orakine Ltd, Dublin, Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations